{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T10:44:35Z","timestamp":1789469075217,"version":"build-2803163510"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s40257-026-01050-1","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T18:13:29Z","timestamp":1782756809000},"page":"879-885","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Defining the Potential for Disease Modification in Atopic Dermatitis"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0853-0252","authenticated-orcid":false,"given":"Eric L.","family":"Simpson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy S.","family":"Paller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar","family":"Palomares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Bieber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,29]]},"reference":[{"issue":"4","key":"1050_CR1","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1111\/jdv.19699","volume":"38","author":"ME Jacobson","year":"2024","unstructured":"Jacobson ME, Seshadri RS, Morimoto R, et al. Early intervention and disease modification in atopic dermatitis: the current state of the field and barriers to progress. J Eur Acad Dermatol Venereol. 2024;38(4):665\u201372. https:\/\/doi.org\/10.1111\/jdv.19699.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"9","key":"1050_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.22271\/tpi.2025.v14.i9a.26256","volume":"14","author":"M Pandey","year":"2025","unstructured":"Pandey M, Bijal P, Salni D, Chirag D. A review on neurodegenerative disease: the race to develop disease modifying drugs for Alzheimer\u2019s and Parkinson\u2019s. Pharma Innov. 2025;14(9):1\u20139. https:\/\/doi.org\/10.22271\/tpi.2025.v14.i9a.26256.","journal-title":"Pharma Innov"},{"issue":"8","key":"1050_CR3","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/s41573-023-00735-0","volume":"22","author":"T Bieber","year":"2023","unstructured":"Bieber T. Disease modification in inflammatory skin disorders: opportunities and challenges. Nat Rev Drug Discov. 2023;22(8):662\u201380. https:\/\/doi.org\/10.1038\/s41573-023-00735-0.","journal-title":"Nat Rev Drug Discov"},{"issue":"12","key":"1050_CR4","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.1007\/s13555-022-00819-6","volume":"12","author":"AN Fasseeh","year":"2022","unstructured":"Fasseeh AN, Elezbawy B, Korra N, et al. Burden of atopic dermatitis in adults and adolescents: a systematic literature review. Dermatol Ther. 2022;12(12):2653\u201368. https:\/\/doi.org\/10.1007\/s13555-022-00819-6.","journal-title":"Dermatol Ther"},{"issue":"1","key":"1050_CR5","doi-asserted-by":"publisher","first-page":"2202288","DOI":"10.1080\/09546634.2023.2202288","volume":"34","author":"ED Bacci","year":"2023","unstructured":"Bacci ED, Correll JR, Pierce EJ, et al. Burden of atopic dermatitis and unmet needs with existing therapies. J Dermatolog Treat. 2023;34(1):2202288. https:\/\/doi.org\/10.1080\/09546634.2023.2202288.","journal-title":"J Dermatolog Treat"},{"issue":"11","key":"1050_CR6","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1111\/jdv.17348","volume":"35","author":"CC von St\u00fclpnagel","year":"2021","unstructured":"von St\u00fclpnagel CC, Augustin M, D\u00fcpmann L, da Silva N, Sommer R. Mapping risk factors for cumulative life course impairment in patients with chronic skin diseases: a systematic review. J Eur Acad Dermatol Venereol. 2021;35(11):2166\u201384. https:\/\/doi.org\/10.1111\/jdv.17348.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"Suppl. 7","key":"1050_CR7","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/jdv.18168","volume":"36","author":"M Augustin","year":"2022","unstructured":"Augustin M, Misery L, von Kobyletzki L, Armario-Hita JC, Mealing S, Redding M. Unveiling the true costs and societal impacts of moderate-to-severe atopic dermatitis in Europe. J Eur Acad Dermatol Venereol. 2022;36(Suppl. 7):3\u201316. https:\/\/doi.org\/10.1111\/jdv.18168.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"1050_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.xjidi.2022.100131","volume":"2","author":"LA Beck","year":"2022","unstructured":"Beck LA, Cork MJ, Amagai M, et al. Type 2 inflammation contributes to skin barrier dysfunction in atopic dermatitis. JID Innov. 2022;2(5):100131. https:\/\/doi.org\/10.1016\/j.xjidi.2022.100131.","journal-title":"JID Innov"},{"issue":"7","key":"1050_CR9","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1007\/s13555-022-00737-7","volume":"12","author":"EB Haddad","year":"2022","unstructured":"Haddad EB, Cyr SL, Arima K, McDonald RA, Levit NA, Nestle FO. Current and emerging strategies to inhibit type 2 inflammation in atopic dermatitis. Dermatol Ther (Heidelb). 2022;12(7):1501\u201333. https:\/\/doi.org\/10.1007\/s13555-022-00737-7.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1050_CR10","unstructured":"Siegfried EC, Bieber T, Paller AS, et al. Clinical remission and off-treatment remission in infants and preschoolers with moderate-to-severe atopic dermatitis treated with dupilumab: preliminary data from an open-label extension study. Poster presented at the 10th Congress of the European Academy of Paediatric Societies (EAPS); 17\u201320 October, 2024; Vienna."},{"key":"1050_CR11","unstructured":"Siegfried EC, Bieber T, Paller AS, et al. Clinical remission and off-treatment remission in pediatric patients with moderate-to-severe atopic dermatitis treated with dupilumab: open-label extension study preliminary data. Poster presented at the 23rd European Society for Pediatric Dermatology (ESPD) Congress; 2\u20134 May, 2024; Kosice."},{"issue":"2","key":"1050_CR12","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1001\/jamadermatol.2019.3617","volume":"156","author":"M Worm","year":"2020","unstructured":"Worm M, Simpson EL, Tha\u00e7i D, et al. Efficacy and safety of multiple dupilumab dose regimens after initial successful treatment in patients with atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020;156(2):131\u201343. https:\/\/doi.org\/10.1001\/jamadermatol.2019.3617.","journal-title":"JAMA Dermatol"},{"issue":"3","key":"1050_CR13","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/bjd.19574","volume":"184","author":"A Wollenberg","year":"2021","unstructured":"Wollenberg A, Blauvelt A, Guttman-Yassky E, et al. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol. 2021;184(3):437\u201349. https:\/\/doi.org\/10.1111\/bjd.19574.","journal-title":"Br J Dermatol"},{"issue":"6","key":"1050_CR14","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1007\/s40257-023-00806-3","volume":"24","author":"EL Simpson","year":"2023","unstructured":"Simpson EL, Pink AE, Blauvelt A, et al. Tralokinumab efficacy over 1 year in adults with moderate-to-severe atopic dermatitis: pooled data from two phase III trials. Am J Clin Dermatol. 2023;24(6):939\u201352. https:\/\/doi.org\/10.1007\/s40257-023-00806-3.","journal-title":"Am J Clin Dermatol"},{"issue":"12","key":"1050_CR15","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1056\/NEJMoa2206714","volume":"388","author":"JI Silverberg","year":"2023","unstructured":"Silverberg JI, Guttman-Yassky E, Tha\u00e7i D, et al. Two phase 3 trials of lebrikizumab for moderate-to-severe atopic dermatitis. N Engl J Med. 2023;388(12):1080\u201391. https:\/\/doi.org\/10.1056\/NEJMoa2206714.","journal-title":"N Engl J Med"},{"issue":"6","key":"1050_CR16","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1093\/bjd\/ljad022","volume":"188","author":"A Blauvelt","year":"2023","unstructured":"Blauvelt A, Thyssen JP, Guttman-Yassky E, et al. Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials. Br J Dermatol. 2023;188(6):740\u20138. https:\/\/doi.org\/10.1093\/bjd\/ljad022.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1050_CR17","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2026.2636417","volume":"37","author":"JI Silverberg","year":"2026","unstructured":"Silverberg JI, Bieber T, Eyerich K, et al. Lebrikizumab off-therapy remission sustained up to 38 weeks in atopic dermatitis. J Dermatol Treat. 2026;37(1):2636417. https:\/\/doi.org\/10.1080\/09546634.2026.2636417.","journal-title":"J Dermatol Treat"},{"issue":"4","key":"1050_CR18","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1016\/j.jaci.2024.10.031","volume":"155","author":"S Weidinger","year":"2025","unstructured":"Weidinger S, Blauvelt A, Papp KA, et al. Phase 2b randomized clinical trial of amlitelimab, an anti-OX40 ligand antibody, in patients with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol. 2025;155(4):1264\u201375. https:\/\/doi.org\/10.1016\/j.jaci.2024.10.031.","journal-title":"J Allergy Clin Immunol"},{"key":"1050_CR19","doi-asserted-by":"publisher","first-page":"3153","DOI":"10.1007\/s13555-025-01492-1","volume":"15","author":"E Guttman-Yassky","year":"2025","unstructured":"Guttman-Yassky E, Simpson E, Esfandiari E, et al. Rocatinlimab: a novel T-cell rebalancing therapy targeting the OX40 receptor in atopic dermatitis. Dermatol Ther. 2025;15:3153\u201371. https:\/\/doi.org\/10.1007\/s13555-025-01492-1.","journal-title":"Dermatol Ther"},{"issue":"2","key":"1050_CR20","doi-asserted-by":"publisher","first-page":"s732","DOI":"10.25251\/v9pqj003","volume":"10","author":"E Guttman-Yassky","year":"2026","unstructured":"Guttman-Yassky E, Bieber T, Gutermuth J, et al. Sustained on- and off-treatment disease control in patients with moderate-to-severe atopic dermatitis following 12-week open-label once-daily abrocitinib 200 mg: post-hoc analysis of the phase 3 JADE REGIMEN study. Skin. 2026;10(2):s732. https:\/\/doi.org\/10.25251\/v9pqj003.","journal-title":"Skin"},{"issue":"2","key":"1050_CR21","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.anai.2024.09.022","volume":"134","author":"T Bieber","year":"2025","unstructured":"Bieber T. The paradigm shift in drug development for atopic dermatitis: addressing the variables of the equation leading to disease modification. Ann Allergy Asthma Immunol. 2025;134(2):144\u201350. https:\/\/doi.org\/10.1016\/j.anai.2024.09.022.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"3","key":"1050_CR22","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/j.jaci.2022.08.026","volume":"151","author":"GP Geba","year":"2023","unstructured":"Geba GP, Li D, Xu M, et al. Attenuating the atopic march: meta-analysis of the dupilumab atopic dermatitis database for incident allergic events. J Allergy Clin Immunol. 2023;151(3):756\u201366. https:\/\/doi.org\/10.1016\/j.jaci.2022.08.026.","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"1050_CR23","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.anai.2017.10.037","volume":"120","author":"DA Hill","year":"2018","unstructured":"Hill DA, Spergel JM. The atopic march. Ann Allergy Asthma Immunol. 2018;120(2):131\u20137. https:\/\/doi.org\/10.1016\/j.anai.2017.10.037.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"4","key":"1050_CR24","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/j.jaad.2024.10.107","volume":"92","author":"UE Choi","year":"2025","unstructured":"Choi UE, Deng J, Parthasarathy V, et al. Risk factors and temporal associations of progression of the atopic march in children with early-onset atopic dermatitis. J Am Acad Dermatol. 2025;92(4):732\u201340. https:\/\/doi.org\/10.1016\/j.jaad.2024.10.107.","journal-title":"J Am Acad Dermatol"},{"issue":"39","key":"1050_CR25","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000005005","volume":"95","author":"C Lee","year":"2016","unstructured":"Lee C, Chen M, Jeng M, et al. Longitudinal association between early atopic dermatitis and subsequent attention-deficit or autistic disorder. Medicine (Baltimore). 2016;95(39):e5005. https:\/\/doi.org\/10.1097\/MD.0000000000005005.","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"1050_CR26","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1111\/all.15818","volume":"79","author":"S Cameron","year":"2024","unstructured":"Cameron S, Donnelly A, Broderick C, et al. Mind and skin: exploring the links between inflammation, sleep disturbance and neurocognitive function in patients with atopic dermatitis. Allergy. 2024;79(1):26\u201336. https:\/\/doi.org\/10.1111\/all.15818.","journal-title":"Allergy"},{"issue":"10","key":"1050_CR27","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1001\/jamadermatol.2021.2657","volume":"157","author":"C Kern","year":"2021","unstructured":"Kern C, Wan J, LeWinn KZ, et al. Association of atopic dermatitis and mental health outcomes across childhood: a longitudinal cohort study. JAMA Dermatol. 2021;157(10):1200\u20138. https:\/\/doi.org\/10.1001\/jamadermatol.2021.2657.","journal-title":"JAMA Dermatol"},{"issue":"1","key":"1050_CR28","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.anai.2020.08.002","volume":"126","author":"V Wang","year":"2021","unstructured":"Wang V, Boguniewicz J, Boguniewicz M, Ong PY. The infectious complications of atopic dermatitis. Ann Allergy Asthma Immunol. 2021;126(1):3\u201312. https:\/\/doi.org\/10.1016\/j.anai.2020.08.002.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"2","key":"1050_CR29","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1111\/jdv.19569","volume":"38","author":"L von Kobyletzki","year":"2024","unstructured":"von Kobyletzki L, Henrohn D, Ballardini N, et al. Comorbidities in childhood atopic dermatitis: a population-based study. J Eur Acad Dermatol Venereol. 2024;38(2):354\u201364. https:\/\/doi.org\/10.1111\/jdv.19569.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"1050_CR30","doi-asserted-by":"publisher","first-page":"40","DOI":"10.21037\/atm-20-4708","volume":"9","author":"D Wu","year":"2021","unstructured":"Wu D, Wu X-D, Zhou X, Huang W, Luo C, Liu Y. Bone mineral density, osteopenia, osteoporosis, and fracture risk in patients with atopic dermatitis: a systematic review and meta-analysis. Ann Transl Med. 2021;9(1):40. https:\/\/doi.org\/10.21037\/atm-20-4708.","journal-title":"Ann Transl Med."},{"key":"1050_CR31","doi-asserted-by":"publisher","DOI":"10.1111\/all.16588","author":"D Fehr","year":"2025","unstructured":"Fehr D, Van Hung H-T, Maintz L, et al. Deciphering the connection between atopic dermatitis and cardiovascular diseases: analysis of clinical associations and cardiometabolic proteins. Allergy. 2025. https:\/\/doi.org\/10.1111\/all.16588.","journal-title":"Allergy"},{"issue":"5","key":"1050_CR32","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/j.jaci.2022.12.002","volume":"151","author":"JP Thyssen","year":"2023","unstructured":"Thyssen JP, Halling A-S, Schmid-Grendelmeier P, Guttman-Yassky E, Silverberg JI. Comorbidities of atopic dermatitis: what does the evidence say? J Allergy Clin Immunol. 2023;151(5):1155\u201362. https:\/\/doi.org\/10.1016\/j.jaci.2022.12.002.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"1050_CR33","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1159\/000533366","volume":"240","author":"Y Cheng","year":"2024","unstructured":"Cheng Y, Lu J, Wang J, Loh C, Chen T. Associations of atopic dermatitis with attention deficit\/hyperactivity disorder and autism spectrum disorder: a systematic review and meta-analysis. Dermatology. 2024;240(1):13\u201325.","journal-title":"Dermatology"},{"issue":"1","key":"1050_CR34","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/pai.12315","volume":"26","author":"JI Silverberg","year":"2015","unstructured":"Silverberg JI. Association between childhood atopic dermatitis, malnutrition, and low bone mineral density: a US population-based study. Pediatr Allergy Immunol. 2015;26(1):54\u201361. https:\/\/doi.org\/10.1111\/pai.12315.","journal-title":"Pediatr Allergy Immunol"},{"issue":"3","key":"1050_CR35","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1111\/all.15577","volume":"78","author":"SW Lee","year":"2023","unstructured":"Lee SW, Shin YH, Shin JI, et al. Fracture incidence in children after developing atopic dermatitis: a Korean nationwide birth cohort study. Allergy. 2023;78(3):871\u20135. https:\/\/doi.org\/10.1111\/all.15577.","journal-title":"Allergy"},{"issue":"2","key":"1050_CR36","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.jaci.2019.10.029","volume":"145","author":"PD Arkwright","year":"2020","unstructured":"Arkwright PD, Mughal MZ. Vertebral, pelvic, and hip fracture risk in adults with severe atopic dermatitis. J Allergy Clin Immunol. 2020;145(2):487\u20138. https:\/\/doi.org\/10.1016\/j.jaci.2019.10.029.","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"1050_CR37","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1001\/jamadermatol.2014.3432","volume":"151","author":"JI Silverberg","year":"2015","unstructured":"Silverberg JI, Paller AS. Association between eczema and stature in 9 US population-based studies. JAMA Dermatol. 2015;151(4):401\u20139. https:\/\/doi.org\/10.1001\/jamadermatol.2014.3432.","journal-title":"JAMA Dermatol"},{"issue":"12","key":"1050_CR38","doi-asserted-by":"publisher","first-page":"3537","DOI":"10.1002\/art.27692","volume":"62","author":"MPM Van der Linden","year":"2010","unstructured":"Van der Linden MPM, le Cessie S, Raza K, et al. Long-term impact of delay in assessment of patients with early arthritis. Arthritis Rheum. 2010;62(12):3537\u201346. https:\/\/doi.org\/10.1002\/art.27692.","journal-title":"Arthritis Rheum"},{"issue":"9","key":"1050_CR39","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1136\/annrheumdis-2011-200736","volume":"71","author":"K Wevers-de Boer","year":"2012","unstructured":"Wevers-de Boer K, Visser K, Heimans L, et al. Remission induction therapy with methotrexate and prednisone in patients with early rheumatoid and undifferentiated arthritis (the IMPROVED study). Ann Rheum Dis. 2012;71(9):1472\u20137. https:\/\/doi.org\/10.1136\/annrheumdis-2011-200736.","journal-title":"Ann Rheum Dis"},{"issue":"9613","key":"1050_CR40","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/S0140-6736(08)60304-9","volume":"371","author":"G D\u2019Haens","year":"2008","unstructured":"D\u2019Haens G, Baert F, van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn\u2019s disease: an open randomised trial. Lancet. 2008;371(9613):660\u20137. https:\/\/doi.org\/10.1016\/S0140-6736(08)60304-9.","journal-title":"Lancet"},{"issue":"14","key":"1050_CR41","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.3748\/wjg.v16.i14.1776","volume":"16","author":"JS Lee","year":"2010","unstructured":"Lee JS, Lee JH, Lee JH, et al. Efficacy of early treatment with infliximab in pediatric Crohn\u2019s disease. World J Gastroenterol. 2010;16(14):1776\u201381. https:\/\/doi.org\/10.3748\/wjg.v16.i14.1776.","journal-title":"World J Gastroenterol"},{"issue":"3","key":"1050_CR42","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1111\/j.1651-2227.2010.01938.x","volume":"100","author":"MJ Kim","year":"2011","unstructured":"Kim MJ, Lee JS, Lee JH, Kim JY, Choe YH. Infliximab therapy in children with Crohn\u2019s disease: a one-year evaluation of efficacy comparing \u2018top-down\u2019 and \u2018step-up\u2019 strategies. Acta Paediatr. 2011;100(3):451\u20135. https:\/\/doi.org\/10.1111\/j.1651-2227.2010.01938.x.","journal-title":"Acta Paediatr"},{"issue":"11","key":"1050_CR43","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1111\/1346-8138.13408","volume":"43","author":"T Fukuie","year":"2016","unstructured":"Fukuie T, Hirakawa S, Narita M, et al. Potential preventive effects of proactive therapy on sensitization in moderate to severe childhood atopic dermatitis: a randomized, investigator-blinded, controlled study. J Dermatol. 2016;43(11):1283\u201392. https:\/\/doi.org\/10.1111\/1346-8138.13408.","journal-title":"J Dermatol"},{"issue":"1","key":"1050_CR44","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.jaci.2023.03.008","volume":"152","author":"K Yamamoto-Hanada","year":"2023","unstructured":"Yamamoto-Hanada K, Kobayashi T, Mikami M, et al. Enhanced early skin treatment for atopic dermatitis in infants reduces food allergy. J Allergy Clin Immunol. 2023;152(1):126\u201335. https:\/\/doi.org\/10.1016\/j.jaci.2023.03.008.","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"1050_CR45","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1016\/j.jaip.2019.11.036","volume":"8","author":"Y Miyaji","year":"2020","unstructured":"Miyaji Y, Yang L, Yamamoto-Hanada K, Narita M, Saito H, Ohya Y. Earlier aggressive treatment to shorten the duration of eczema in infants resulted in fewer food allergies at 2 years of age. J Allergy Clin Immunol Pract. 2020;8(5):1721-4.e6. https:\/\/doi.org\/10.1016\/j.jaip.2019.11.036.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"11","key":"1050_CR46","doi-asserted-by":"publisher","first-page":"2697","DOI":"10.1007\/s13555-023-01016-9","volume":"13","author":"MJ Cork","year":"2023","unstructured":"Cork MJ, Tha\u00e7i D, Eichenfield LF, et al. Dupilumab safety and efficacy in a phase III open-label extension trial in children 6\u201311 years of age with severe atopic dermatitis. Dermatol Ther (Heidelb). 2023;13(11):2697\u2013719. https:\/\/doi.org\/10.1007\/s13555-023-01016-9.","journal-title":"Dermatol Ther (Heidelb)."},{"issue":"3","key":"1050_CR47","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.jaad.2024.05.029","volume":"91","author":"T-L Lin","year":"2024","unstructured":"Lin T-L, Fan Y-H, Fan K-S, Juan C-K, Chen Y-J, Wu C-Y. Reduced atopic march risk in pediatric atopic dermatitis patients prescribed dupilumab versus conventional immunomodulatory therapy: a population-based cohort study. J Am Acad Dermatol. 2024;91(3):466\u201373. https:\/\/doi.org\/10.1016\/j.jaad.2024.05.029.","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"1050_CR48","doi-asserted-by":"publisher","first-page":"2748","DOI":"10.1111\/all.16265","volume":"79","author":"SY-C Tsai","year":"2024","unstructured":"Tsai SY-C, Gaffin JM, Hawryluk EB, et al. Evaluation of dupilumab on the disease burden in children and adolescents with atopic dermatitis: a population-based cohort study. Allergy. 2024;79(10):2748\u201358. https:\/\/doi.org\/10.1111\/all.16265.","journal-title":"Allergy"},{"issue":"16","key":"1050_CR49","doi-asserted-by":"publisher","first-page":"4639","DOI":"10.3390\/jcm11164639","volume":"11","author":"S Mastraftsi","year":"2022","unstructured":"Mastraftsi S, Vrioni G, Bakakis M, et al. Atopic dermatitis: striving for reliable biomarkers. J Clin Med. 2022;11(16):4639. https:\/\/doi.org\/10.3390\/jcm11164639.","journal-title":"J Clin Med"},{"issue":"3","key":"1050_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.47363\/JDMRS\/2024(5)154","volume":"5","author":"G Alvin","year":"2024","unstructured":"Alvin G, Chan M. The role of the thymus gland in atopic dermatitis. J Dermatol Res Rev Rep. 2024;5(3):1\u20135. https:\/\/doi.org\/10.47363\/JDMRS\/2024(5)154.","journal-title":"J Dermatol Res Rev Rep."},{"issue":"3","key":"1050_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.waojou.2021.100519","volume":"14","author":"A Wollenberg","year":"2021","unstructured":"Wollenberg A, Thomsen SF, Lacour J-P, Jaumont X, Lazarewicz S. Targeting immunoglobulin E in atopic dermatitis: a review of the existing evidence. World Allergy Org J. 2021;14(3):100519. https:\/\/doi.org\/10.1016\/j.waojou.2021.100519.","journal-title":"World Allergy Org J."},{"issue":"1","key":"1050_CR52","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s13223-021-00531-8","volume":"17","author":"A Sweeney","year":"2021","unstructured":"Sweeney A, Sampath V, Nadeau KC. Early intervention of atopic dermatitis as a preventative strategy for progression of food allergy. Allergy Asthma Clin Immunol. 2021;17(1):30. https:\/\/doi.org\/10.1186\/s13223-021-00531-8.","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"6","key":"1050_CR53","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1016\/j.jaci.2022.11.023","volume":"151","author":"A-S Halling","year":"2023","unstructured":"Halling A-S, Rinnov MR, Ruge IF, et al. Skin TARC\/CCL17 increase precedes the development of childhood atopic dermatitis. J Allergy Clin Immunol. 2023;151(6):1550-7.e6. https:\/\/doi.org\/10.1016\/j.jaci.2022.11.023.","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"1050_CR54","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.23214","volume":"34","author":"Y Hu","year":"2020","unstructured":"Hu Y, Liu S, Liu P, Mu Z, Zhang J. Clinical relevance of eosinophils, basophils, serum total IgE level, allergen-specific IgE, and clinical features in atopic dermatitis. J Clin Lab Anal. 2020;34(6):e23214. https:\/\/doi.org\/10.1002\/jcla.23214.","journal-title":"J Clin Lab Anal"},{"issue":"3","key":"1050_CR55","doi-asserted-by":"publisher","first-page":"AB61","DOI":"10.1016\/j.jaad.2024.07.250","volume":"91","author":"B Kim","year":"2024","unstructured":"Kim B, Beck LA, Simpson EL, et al. 53117 lower total IgE after dupilumab treatment is associated with a reduction in flares in patients with moderate-to-severe atopic dermatitis. J Am Acad Dermatol. 2024;91(3):AB61. https:\/\/doi.org\/10.1016\/j.jaad.2024.07.250.","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"1050_CR56","doi-asserted-by":"publisher","DOI":"10.1002\/clt2.12381","volume":"14","author":"LP van der Rijst","year":"2024","unstructured":"van der Rijst LP, Hillbrands MS, Zuithoff NPA, et al. Dupilumab induces a significant decrease of food specific immunoglobulin E levels in pediatric atopic dermatitis patients. Clin Transl Allergy. 2024;14(7):e12381. https:\/\/doi.org\/10.1002\/clt2.12381.","journal-title":"Clin Transl Allergy"},{"issue":"6","key":"1050_CR57","doi-asserted-by":"publisher","DOI":"10.1111\/pai.14178","volume":"35","author":"LP van der Rijst","year":"2024","unstructured":"van der Rijst LP, de Winter- Groot KM, Zuithoff NPA, de Bruin-Weller MS, de Graaf M. Effect of dupilumab on asthma and aeroallergen sensitization in pediatric atopic dermatitis patients: results of the BioDay registry. Pediatr Allergy Immunol. 2024;35(6):e14178. https:\/\/doi.org\/10.1111\/pai.14178.","journal-title":"Pediatr Allergy Immunol"},{"issue":"5","key":"1050_CR58","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1016\/j.jaci.2024.06.023","volume":"154","author":"ME Starrenburg","year":"2024","unstructured":"Starrenburg ME, Bel Imam M, Lopez JF, et al. Dupilumab treatment decreases MBC2s, correlating with reduced IgE levels in pediatric atopic dermatitis. J Allergy Clin Immunol. 2024;154(5):1333-8.e4. https:\/\/doi.org\/10.1016\/j.jaci.2024.06.023.","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"1050_CR59","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1111\/cea.14442","volume":"54","author":"CM Boesjes","year":"2024","unstructured":"Boesjes CM, Bakker DS, Knol EF, de Graaf M, van Wijk F, de Bruin-Weller MS. Differential dynamics of TARC during JAK-inhibitor therapy compared to biological therapies targeting type 2 inflammation. Clin Exp Allergy. 2024;54(4):294\u20136. https:\/\/doi.org\/10.1111\/cea.14442.","journal-title":"Clin Exp Allergy"},{"issue":"5","key":"1050_CR60","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/j.jaad.2025.01.052","volume":"92","author":"T Hagino","year":"2025","unstructured":"Hagino T, Saeki H, Fujimoto E, Kanda N. A 96-week real-world outcome of upadacitinib treatment for atopic dermatitis: systemic therapy-na\u00efve versus experienced patients. J Am Acad Dermatol. 2025;92(5):1049\u201355. https:\/\/doi.org\/10.1016\/j.jaad.2025.01.052.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"1050_CR61","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1159\/000536335","volume":"185","author":"L Mart\u00edn-Cruz","year":"2024","unstructured":"Mart\u00edn-Cruz L, Benito-Villalvilla C, Sirvent S, Angelina A, Palomares O. The role of regulatory T cells in allergic diseases: Collegium Internationale Allergologicum (CIA) update 2024. Int Arch Allergy Immunol. 2024;185(5):503\u201318. https:\/\/doi.org\/10.1159\/000536335.","journal-title":"Int Arch Allergy Immunol"},{"key":"1050_CR62","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-12-125","volume":"12","author":"H Zhang","year":"2014","unstructured":"Zhang H, Kong H, Zeng X, Guo L, Sun X, He S. Subsets of regulatory T cells and their roles in allergy. J Transl Med. 2014;12:125. https:\/\/doi.org\/10.1186\/1479-5876-12-125.","journal-title":"J Transl Med"},{"issue":"1","key":"1050_CR63","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-53384-1","volume":"15","author":"JI Silverberg","year":"2024","unstructured":"Silverberg JI, Rosmarin D, Chovatiya R, et al. The regulatory T cell-selective interleukin-2 receptor agonist rezpegaldesleukin in the treatment of inflammatory skin diseases: two randomized, double-blind, placebo-controlled phase 1b trials. Nat Commun. 2024;15(1):9230. https:\/\/doi.org\/10.1038\/s41467-024-53384-1.","journal-title":"Nat Commun"},{"issue":"5","key":"1050_CR64","doi-asserted-by":"publisher","DOI":"10.1002\/clt2.70062","volume":"15","author":"D Redhu","year":"2025","unstructured":"Redhu D, Francuzik W, Globig P, Worm M. T cell immunophenotypes and IgE responses in patients with moderate-to-severe atopic dermatitis receiving dupilumab. Clin Transl Allergy. 2025;15(5):e70062. https:\/\/doi.org\/10.1002\/clt2.70062.","journal-title":"Clin Transl Allergy"},{"key":"1050_CR65","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2026.0662","author":"JF Merola","year":"2026","unstructured":"Merola JF, Childs BA, Bartley BR, et al. International Eczema Council definitions of low disease activity and remission in atopic dermatitis: a consensus statement. JAMA Dermatol. 2026. https:\/\/doi.org\/10.1001\/jamadermatol.2026.0662.","journal-title":"JAMA Dermatol"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-026-01050-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-026-01050-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-026-01050-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T09:32:03Z","timestamp":1789464723000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-026-01050-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,29]]},"references-count":65,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1050"],"URL":"https:\/\/doi.org\/10.1007\/s40257-026-01050-1","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,29]]},"assertion":[{"value":"6 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Open Access funding was enabled and organized by Sanofi and Regeneron Pharmaceuticals Inc.","order":1,"name":"Ethics","label":"Funding","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is based on content developed and presented by the authors at the 2025 Global ADVENT Forum. The ADVENT program is funded and facilitated by Sanofi and Regeneron Pharmaceuticals Inc. Eric L. Simpson has served as a principal investigator for and\/or received grants from AbbVie, Acrotech, Amgen, Arcutis, ASLAN, Castle, CorEvitas, Dermavant, Dermira, Eli Lily, Incyte, Pfizer, Regeneron Pharmaceuticals Inc., Sanofi, Target, and Veriskin; and has received personal fees from AbbVie, Amgen, Arcutis, Astria Therapeutics, Castle, CorEvitas, Dermira, Eli Lilly, FIDE, Impetus Healthcare, Incyte, Innovaderm Recherches\/Indero, Janssen, LEO, Numab Therapeutics AG, Pfizer, Recludix Pharma, Regeneron Pharmaceuticals Inc., Roche Products Ltd, Sanofi, and Sitryx Therapeutics. Amy S. Paller has served as an investigator for AbbVie, BioMendics, Dermavant, Eli Lilly, Incyte, Johnson & Johnson Innovative Medicine, Regeneron Pharmaceuticals Inc., and UCB; as a consultant for Abeona, Arcutis, BioCryst, Boehringer Ingelheim, Castle Creek, Chiesi, Dermavant, Johnson & Johnson Innovative Medicine, Krystal, LEO, Lilly, L\u2019Or\u00e9al, MoonLake Immunotherapeutics, Pelthos, Quoin, Regeneron Pharmaceuticals Inc., and Sanofi; and as a data safety monitoring board member for AbbVie, Abeona, BioCryst, Daiichi Sankyo, and Galderma. Amy Paller is an Editorial Board member of the\n                      American Journal of Clinical Dermatology\n                      and was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Oscar Palomares has received speaker and\/or consulting fees from AstraZeneca, GSK, Immunotek S.L., Novartis, Pfizer, Regeneron Pharmaceuticals Inc., and Sanofi. Thomas Bieber has received consultant fees from AbbVie, Affibody, Amagma, AnaptysBio, Anergis, AOBiome, Apogee Therapeutics, Arena Pharmaceuticals, Aristea, Artax Biopharma, Asana BioSciences, ASLAN Pharmaceuticals, Astria TX, Attovia Therapeutics, Bayer, BioVersys, Boehringer Ingelheim, Bristol Myers Squibb, BYOME Labs, Connect Biopharma, Daiichi Sankyo, Dermavant, DICE Therapeutics, Domain Therapeutics, DS Biopharma, EQRx, Galapagos, Galderma, Glenmark, GSK, Incyte, Innovaderm, Janssen, Kirin, Kymab, LG Chem, Medac, Micreos, MSD, Nektar Therapeutics, Novartis, Numab Therapeutics, OM Pharma, Overton, Pierre Fabre, Q32 Bio, RAPT Therapeutics, Samsung Bioepis, Sanofi, TIRmed Pharma, UCB, UNION Therapeutics, Upstream Bio, and Yuhan; and speaker fees and consultant fees from Almirall, LEO Pharma, Lilly, Pfizer, and Sanofi-Regeneron Pharmaceuticals Inc.","order":2,"name":"Ethics","label":"Conflicts of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study does not contain any personal data that require consent for publication.","order":5,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Availability of Data and Material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":7,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors contributed equally to the conception, design, drafting, and critical revision of the manuscript. All authors approved the final version.","order":8,"name":"Ethics","label":"Authors\u2019 Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}